

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

**SHANGHAI INTERNATIONAL
SHANGHAI GROWTH INVESTMENT LIMITED**

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 770)

**RESIGNATION OF EXECUTIVE DIRECTOR,
CHANGE OF AUTHORISED REPRESENTATIVE, AND
CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE
AND INVESTMENT COMMITTEE**

The Board hereby announces that with effect from 23 March 2022:

1. Dr. WANG Ching has resigned as an Executive Director and the Authorised Representative of the Company. He also ceased to be a member of the Remuneration Committee and the Investment Committee of the Company with effect from the same date;
2. Mr. ZHAO Tian, an Executive Director, has been appointed as the Authorised Representative of the Company; and
3. Mr. CHOW Wang, a Fund Manager of the Company's Investment Manager has been appointed as a member of the Investment Committee of the Company.

RESIGNATION OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Shanghai International Shanghai Growth Investment Limited (the “**Company**”) hereby announces that due to retirement, Dr. WANG Ching (“**Dr. WANG**”) has resigned as an Executive Director and authorised representative (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and ceased to be a member of the Remuneration Committee and the Investment Committee of the Company with effect from 23 March 2022.

Dr. WANG has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude to Dr. WANG for his valuable contribution to the Company during his tenure of office.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board is pleased to announce that Mr. ZHAO Tian (“**Mr. ZHAO**”), an Executive Director of the Company, has been appointed as the Authorised Representative of the Company under Rule 3.05 of the Listing Rules to fill the vacancy arising from the resignation of Dr. WANG with effect from 23 March 2022.

CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE

Following the resignation of Dr. WANG as an Executive Director, he has ceased to act as a member of the Company’s Remuneration Committee. With effect from 23 March 2022, the Remuneration Committee comprises of Independent Non-executive Directors, namely, Mr. ONG Ka Thai (Chairman), Mr. YICK Wing Fat Simon and Dr. HUA Min, and Mr. ZHAO Tian (Executive Director).

CHANGE IN COMPOSITION OF INVESTMENT COMMITTEE

Following the resignation of Dr. WANG as an Executive Director, he has ceased to act as a member of the Company’s Investment Committee. The Board is pleased to announce that Mr. CHOW Wang (“**Mr. CHOW**”) has been appointed as a member of the Investment Committee to fill the vacancy arising from the resignation of Dr. WANG with effect from 23 March 2022.

Mr. CHOW rejoined Shanghai International Asset Management (Hong Kong) Company Limited (“**SIAM**” or the Company’s “**Investment Manager**”), in 2018 as a fund manager (“**Fund Manager**”) to perform investment management function including securities investment, portfolio management, and stock analysis in particular in relation to Greater China region. Mr. CHOW is currently one of SIAM’s licensed responsible officers registered with The Securities and Futures Commission (“**SFC**”) to carry out advising in securities (type 4) and asset management (type 9) regulated activities.

Mr. CHOW had been an investment analyst of SIAM from 2004 to 2006. Thereafter, he served a number of sizable foreign fund houses, including the then 4th largest Asia hedge fund, Ward Ferry Management Limited and the award-winning (from Asian Investor’s) hedge fund, Triskele Capital Management Limited, which managed China funds with asset sizes exceeding US\$2 billion. He was responsible for formulating investment strategies, in depth analysis and recommendations on stock selection and asset allocation in particular focus on listed securities traded in Greater China region.

Mr. CHOW possesses effluent experience in the fund management and investment portfolio analysis in the financial sector given that he obtained his representative licenses from the SFC to carry out regulated activities since 2004.

Mr. CHOW holds a Master of Business (Banking & Finance) from The Monash University, Australia in 2001. He graduated from University of Auckland, New Zealand with a Bachelor of Engineering (Electrical & Electronic) in 1997.

Following the abovementioned changes, the Investment Committee comprises of Mr. ZHAO Tian (Executive Director), Mr. LU Xuefang (Non-executive Director) and Mr. CHOW Wang (Fund Manager of the Investment Manager).

The Board would like to extend its welcome to Mr. ZHAO on his new appointment in the Company and Mr. CHOW in joining the Investment Committee of the Company.

By Order of the Board
SHANGHAI INTERNATIONAL
SHANGHAI GROWTH INVESTMENT LIMITED
ZHAO Tian
Executive Director

Hong Kong, 23 March 2022

As at the date of this announcement, the Board comprises Mr. ZHAO Tian as Executive Director; Mr. LU Xuefang as Non-executive Director; and Dr. HUA Min, Mr. ONG Ka Thai and Mr. YICK Wing Fat Simon as Independent Non-executive Directors.